Lundbeck to trial migraine drug in young people

A new phase III trial in the US will investigate whether extending the patient target group of Lundbeck's drug Vyepti to include younger patients is possible.

Lundbeck's headquarters in Valby, Copenhagen | Photo: Lundbeck / PR

285 participants aged 12-17 will test Lundbeck's drug Vyepti as a preventative treatment for migraines over the next year.

This was revealed when Lundbeck registered the study at, a publicly run database of trials of approved medicines.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP recommends nine new drugs, rejects one

Roche and Biogen are among the companies that have received recommendation for approval from the European Medicines Agency's committee (CHMP) at its September meeting. One Pfizer drug was the sole candidate to be rejected.

CEO at WSA: No clarity on EQT exit plans yet

The time horizon for the venture fund EQT's investment in WS Audiology should be ending soon, but according to Group CEO Eric Bernard, there is no clarity on when the potential changes might occur.

Further reading

Related articles

Trial banner

Latest news

See all jobs